Cargando…

Cytotoxicity of Human Hepatic Intrasinusoidal CD56(bright) Natural Killer Cells against Hepatocellular Carcinoma Cells

Hepatic intrasinusoidal (HI) natural killer (NK) cells from liver perfusate have unique features that are similar to those of liver-resident NK cells. Previously, we have reported that HI CD56(bright) NK cells effectively degranulate against SNU398 hepatocellular carcinoma (HCC) cells. Thus, the aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Shin, Han, Jaeseok, Baek, Ji-Seok, Tak, Eunyoung, Song, Gi-Won, Lee, Sung-Gyu, Jung, Dong-Hwan, Park, Gil-Chun, Ahn, Chul-Soo, Kim, Nayoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480584/
https://www.ncbi.nlm.nih.gov/pubmed/30925759
http://dx.doi.org/10.3390/ijms20071564
Descripción
Sumario:Hepatic intrasinusoidal (HI) natural killer (NK) cells from liver perfusate have unique features that are similar to those of liver-resident NK cells. Previously, we have reported that HI CD56(bright) NK cells effectively degranulate against SNU398 hepatocellular carcinoma (HCC) cells. Thus, the aim of this study was to further investigate the phenotype and function of HI NK cells. We found that HI CD56(bright) NK cells degranulated much less to Huh7 cells. HI CD56(bright) NK cells expressed NKG2D, NKp46, TNF-related apoptosis-inducing ligand (TRAIL), and FAS ligand (FASL) at higher levels than CD56(dim) cells. SNU398 cells expressed more NKG2D ligands and FAS and less PD-L1 than Huh7 cells. Blockade of NKG2D, TRAIL, and FASL significantly reduced the cytotoxicity of HI NK cells against SNU398 cells, but blockade of PD-L1 did not lead to any significant change. However, HI NK cells produced IFN-γ well in response to Huh7 cells. In conclusion, the cytotoxicity of HI CD56(bright) NK cells was attributed to the expression of NKG2D, TRAIL, and FASL. The results suggest the possible use of HI NK cells for cancer immunotherapy and prescreening of HCC cells to help identify the most effective NK cell therapy recipients.